Recently added Catalysts

CAZ104

Phase 1

Undisclosed | Small molecule | Other |Pfizer, Inc.|Trials Updated: Sep 1, 2017

CAZ104 development status

Highest phase Phase 1

Registered trials 3 across 1 sponsor since Feb 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED

Total Trials2

Total Enrollment88

FDA Designations

No designations recorded

CAZ104 clinical trials

CAZ104 · 2 trials · 1 indication

Phase 1 2

NCT01430910A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and SeparatelyHealthy

COMPLETED43 Analytics

NCT01395420Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and PlasmaHealthy

COMPLETED45 Analytics

PHASE1COMPLETED

A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately

Healthy

NCT0143091043

Unlock trial analytics

PHASE1COMPLETED

Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma

Healthy

NCT0139542045

Unlock trial analytics

Study Endpoints

Primary Endpoints

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including maximum plasma concentration (Cmax)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including time of Cmax (tmax)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including minimum plasma concentration (Cmin)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including time of Cmin (tmin)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including last quantifiable plasma concentration (Clast)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including time of Clast (tlast)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including average plasma concentration during a dosing interval (Cavg)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including fluctuation index

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including area under the curve of plasma drug concentration (AUC) - time curve from zero to the time of the last quantifiable concentration

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including AUC, Day 1 only

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including AUC during the dosing interval [AUC(0-τ)]

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including terminal half-life (t1/2)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including systemic plasma clearance (CL)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including volume of distribution at steady state (Vss)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including volume of distribution at the terminal phase (Vz)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including accumulation ratio for Cmax and AUC(0-τ)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including linearity index

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Urine pharmacokinetic variables will be measured including amount of drug excreted unchanged into urine from zero to time t [Ae(0-t)]

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Urine pharmacokinetic variables will be measured including fraction of dose excreted unchanged into urine (fe; % dose)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Urine pharmacokinetic variables will be measured including renal clearance (CLR)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Cmax

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including tmax

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Cmin

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including tmin

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Clast

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including tlast

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Cavg

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including fluctuation index

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including AUC(0-t)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including AUC, Day 1 only

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including AUC(0-τ)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including t1/2

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including CL

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Vss

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Vz

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including accumulation ratio for Cmax and AUC(0-τ)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including linearity index

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Urine pharmacokinetic variables will be measured including Ae(0-t)

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Urine pharmacokinetic variables will be measured including fe; % dose

Up to 24 hours post last dose

Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Urine pharmacokinetic variables will be measured including CLR

Up to 24 hours post last dose

Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including Cmax

Up to 24 hours post last dose

Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Urine pharmacokinetic variables will be measured including Ae(0-t)

Up to 24 hours post last dose

To measure and compare the concentration of Avibactam and Ceftazidime in ELF and plasma

at several timepoints from pre-dose up to 5 days post dose (Part 2)

To measure and compare the concentration of Avibactam and Ceftazidime in ELF and plasma by assessment of maximum concentration (Cmax), time to Cmax (tmax), area under the concentration time curve during a dosing interval t (AUCτ), terminal half life (t½λz) in plasma and ELF, plasma clearance (CL), volume of distribution at steady state (Vss) and at the terminal phase (Vz) in plasma, ratio of Cmax in ELF over Cmax in plasma and ratio of AUCτ in ELF over AUCτ in plasma.

Secondary Endpoints

To assess safety and tolerability of Avibactam by assessment of Adverse events

Up to 24 hours post last dose

To assess safety and tolerability of Avibactam by clinical laboratory assessments

Up to 24 hours post last dose

To assess safety and tolerability of Avibactam by assessment of vital signs

Up to 24 hours post last dose

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED

MaskingNONE

ModelPARALLEL

PurposeBASIC_SCIENCE

Treatment Arms

Arm	Type	Description
1	EXPERIMENTAL	CAZ104 (2000mg Ceftazidime/500mg Avibactam)
2	ACTIVE_COMPARATOR	500mg Avibactam
3	ACTIVE_COMPARATOR	2000mg Ceftazidime

Interventions

Name	Type	Description
CAZ104	DRUG	IV infusion
Avibactam	DRUG	IV infusion
Ceftazidime	DRUG	IV infusion

Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years

SexALL

Healthy VolunteersYes

Study Sites1

Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures * Healthy male and female subjects aged 18 to 50 years with veins suitable for cannulation or repeated venepuncture; female subjects must be postmenopausal or surgically sterile. Fem...

Countries:United Kingdom

Unlock Eligibility Criteria

Frequently asked questions about CAZ104

What is CAZ104?

CAZ104 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in Phase 1 clinical trials involving healthy adult volunteers. The specific disease indications for CAZ104 have not been publicly disclosed, and the program's trials are listed as completed.

Who makes CAZ104?

CAZ104 is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer sponsored the Phase 1 clinical trials of CAZ104 conducted in the United Kingdom, including studies NCT01430910 and NCT01395420.

What phase is CAZ104 in?

CAZ104 is in Phase 1 clinical development. Two Phase 1 trials have been conducted, both listed as completed, with a combined enrollment of 88 healthy adult participants. The studies took place in the United Kingdom and included active-controlled, randomized designs.

What clinical trials is CAZ104 in?

CAZ104 has been evaluated in two completed Phase 1 trials. NCT01430910 assessed blood levels of two antibiotics given together and separately in 43 healthy volunteers. NCT01395420 measured concentrations of avibactam and ceftazidime in epithelial lining fluid and plasma in 45 healthy volunteers. Both trials were conducted in the United Kingdom.

Is CAZ104 FDA approved?

CAZ104 is an investigational drug and has not been approved by the FDA. It remains in Phase 1 clinical development, with two completed Phase 1 trials in healthy volunteers. No approval status beyond the investigational stage has been established for CAZ104.

Explore more on BiopharmaWatch

Pfizer, Inc. (PFE)Pipeline, catalysts, financials, insiders and news Biotech disease mapWho is developing what in each indication, and how crowded it is FDA calendarUpcoming PDUFA dates, AdComs and approval odds PDUFA calendarEvery scheduled FDA decision date, month by month Historical FDA calendarPast decisions and how the stock moved on each Catalyst SyncUpcoming readouts and decisions, screened by runway and phase Biotech stock screenerFilter by clinical phase, cash runway and market cap Drugs A to ZEvery drug page starting with C Companies A to ZEvery biotech and pharma company we track

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

Getting Started

News

Blogs

Modality Leaderboard

Disease Map

API

Discord

Recent Updates

Recently added Catalysts

CAZ104

CAZ104 development status

Success Probability

Market & Valuation

Trial Design

FDA Designations

CAZ104 clinical trials

Study Endpoints

Primary Endpoints

Secondary Endpoints

Study Design & Arms

Treatment Arms

Interventions

Eligibility Criteria

Frequently asked questions about CAZ104

What is CAZ104?

Who makes CAZ104?

What phase is CAZ104 in?

What clinical trials is CAZ104 in?

Is CAZ104 FDA approved?

Explore more on BiopharmaWatch